| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BETVII |
| Uniprot No | P43187 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-205aa |
| 氨基酸序列 | MPCSTEAMEKAGHGHASTPRKRSLSNSSFRLRSESLNTLRLRRIFDLFDK NSDGIITVDELSRALNLLGLETDLSELESTVKSFTREGNIGLQFEDFISL HQSLNDSYFAYGGEDEDDNEEDMRKSILSQEEADSFGGFKVFDEDGDGYI SARELQMVLGKLGFSEGSEIDRVEKMIVSVDSNRDGRVDFFEFKDMMRSV LVRSS |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BETVII重组蛋白的模拟参考文献示例(文献为虚构，仅供格式参考)：
---
1. **文献名称**: "Expression and Immunological Characterization of Recombinant BETVII Protein in Escherichia coli"
**作者**: Smith A, et al.
**摘要**: 本研究利用大肠杆菌表达系统成功重组表达了BETVII蛋白，并验证其抗原性。实验表明重组BETVII能够与过敏患者血清中的IgE抗体特异性结合，提示其在过敏诊断中的潜在应用价值。
2. **文献名称**: "Structural Analysis of BETVII Reveals Key Epitopes for Antibody Recognition"
**作者**: Zhang L, et al.
**摘要**: 通过X射线晶体学解析了BETVII重组蛋白的三维结构，鉴定了其表面关键抗原表位。研究为基于表位的免疫疗法设计提供了分子基础。
3. **文献名称**: "Recombinant BETVII as a Therapeutic Vaccine Candidate for Allergic Diseases"
**作者**: Müller C, et al.
**摘要**: 在小鼠模型中评估了重组BETVII蛋白的免疫调节作用，证明其可通过诱导调节性T细胞抑制Th2型免疫反应，降低过敏症状严重程度。
4. **文献名称**: "High-Yield Production of Recombinant BETVII Using a Plant-Based Expression System"
**作者**: Tanaka K, et al.
**摘要**: 开发了一种基于植物瞬时表达的BETVII重组蛋白生产方法，实现了高产量和低内毒素水平的规模化制备，适用于临床级蛋白生产。
---
**注意**：以上文献为示例性质，实际研究中请通过学术数据库(如PubMed、Google Scholar)检索真实文献。建议结合具体研究方向补充关键词(如“过敏原”“结构功能”“重组表达”等)。
BETVII recombinant protein is a engineered version of the Bromodomain and Extra-Terminal (BET) family protein, specifically targeting isoform VII. BET proteins are epigenetic regulators characterized by tandem bromodomains that recognize acetylated lysine residues on histones, facilitating transcriptional activation and chromatin remodeling. The BET family, including BRD2. BRD3. BRD4. and BRDT, plays critical roles in cell cycle progression, inflammation, and oncogenesis by modulating gene expression programs. BETVII, though less extensively studied than BRD4. shares conserved structural features, including two bromodomains and an extraterminal domain, enabling interactions with acetylated histones and transcriptional machinery.
Recombinant BETVII is typically produced using heterologous expression systems (e.g., E. coli or mammalian cells) to ensure high purity and activity. Its production enables detailed biochemical studies, inhibitor screening, and structural analyses to elucidate isoform-specific functions. BET proteins are therapeutic targets due to their involvement in diseases like cancer, autoimmune disorders, and viral infections. BETVII-specific research may uncover unique regulatory mechanisms or binding partners distinct from other BET isoforms, potentially informing selective drug design.
Current BET inhibitors (e.g., JQ1) broadly target bromodomains across isoforms, but isoform-selective compounds are sought to minimize off-target effects. Studying recombinant BETVII aids in mapping ligand-binding interfaces and optimizing inhibitors. Additionally, BETVII's role in specific cellular pathways, such as DNA damage response or differentiation, remains an active area of investigation. Its recombinant form serves as a vital tool for in vitro assays, structural biology (e.g., X-ray crystallography), and high-throughput screening platforms, accelerating both basic research and drug discovery efforts targeting epigenetic dysregulation.
×
